Syndax
  • Home
  • About Us
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Vision, Mission, and Values
  • Pipeline
    • Back
    • Pipeline
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Back
    • Clinical Trials
    • Revumenib Clinical Trials
      • Back
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Back
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Back
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Back
      • Financial Overview
      • SEC Filings
      • Annual Reports & Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Back
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • FAQs
    • Contact Us
  • Contact Us
Syndax
Contact Us
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Vision, Mission, and Values
  • Pipeline
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • FAQs
    • Contact Us
  • Join Us

Determined to realize a future in which people with cancer live longer and better than ever before.


  • What is SNDX-5613?
  • What is axatilimab?
  • What clinical trials is Syndax currently conducting?
  • Who is on the leadership team at Syndax?
  • Where can I see your product pipeline?
  • Where can I find the latest corporate presentation?
  • What is the vision of Syndax?
  • Is Syndax hiring?
  • How can my organization collaborate with Syndax?
  • What is entinostat?
Pipeline
Leadership
Clinical Trials
Publications

01.04.23

Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference

12.14.22

Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12.10.22

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

12.08.22

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

© 2023 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • Investors
  • Career Opportunities